IL190478A0 - Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection - Google Patents

Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection

Info

Publication number
IL190478A0
IL190478A0 IL190478A IL19047808A IL190478A0 IL 190478 A0 IL190478 A0 IL 190478A0 IL 190478 A IL190478 A IL 190478A IL 19047808 A IL19047808 A IL 19047808A IL 190478 A0 IL190478 A0 IL 190478A0
Authority
IL
Israel
Prior art keywords
hepatitis
infection
prevention
treatment
methods
Prior art date
Application number
IL190478A
Other languages
English (en)
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of IL190478A0 publication Critical patent/IL190478A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL190478A 2005-09-30 2008-03-27 Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection IL190478A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72267905P 2005-09-30 2005-09-30
US78754906P 2006-03-29 2006-03-29
PCT/US2006/038823 WO2007041632A2 (en) 2005-09-30 2006-10-02 Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection

Publications (1)

Publication Number Publication Date
IL190478A0 true IL190478A0 (en) 2008-11-03

Family

ID=37906852

Family Applications (1)

Application Number Title Priority Date Filing Date
IL190478A IL190478A0 (en) 2005-09-30 2008-03-27 Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection

Country Status (13)

Country Link
US (1) US7754685B2 (cg-RX-API-DMAC7.html)
EP (1) EP1933859A2 (cg-RX-API-DMAC7.html)
JP (1) JP5517454B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080059270A (cg-RX-API-DMAC7.html)
CN (1) CN105169369B (cg-RX-API-DMAC7.html)
AU (1) AU2006299426B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0616476A2 (cg-RX-API-DMAC7.html)
CA (1) CA2623865A1 (cg-RX-API-DMAC7.html)
IL (1) IL190478A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ567262A (cg-RX-API-DMAC7.html)
RU (1) RU2440822C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007041632A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200803493B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
DK1802650T3 (da) * 2004-10-01 2012-02-06 Scynexis Inc 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
US7754685B2 (en) 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
DK2023918T3 (da) 2006-05-19 2011-04-26 Scynexis Inc Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
JP2009539292A (ja) * 2006-06-02 2009-11-12 ぺリション、クロード、アニー 活性電子の管理
CA2659461A1 (en) * 2006-08-25 2008-02-28 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
JP2010526143A (ja) 2007-05-04 2010-07-29 バーテックス ファーマシューティカルズ インコーポレイテッド Ｈｃｖ感染の処置のための併用療法
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
WO2010002428A2 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
KR101068160B1 (ko) * 2008-12-30 2011-09-27 건국대학교 산학협력단 Ｃ형 간염 바이러스 ｒｎａ핵산 중합효소의 활성을 저해하는 신규 플라보놀 유도체
JP5780969B2 (ja) 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド シクロスポリンａの誘導体
MX2011007194A (es) * 2009-01-07 2013-07-12 Scynexis Inc Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
JP2014520835A (ja) 2011-07-15 2014-08-25 ビーエーエスエフ ソシエタス・ヨーロピア 動物有害生物を駆除するための置換３−ピリジルチアゾール化合物および誘導体ｉを使用した有害生物防除方法
RU2639388C1 (ru) * 2016-10-11 2017-12-21 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Композиция для терапии вирусного гепатита С
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
CN114245744A (zh) * 2020-04-15 2022-03-25 睿诺医疗科技（上海）有限公司 器官损伤的预防和治疗

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159219A1 (en) 1993-03-31 1994-10-13 Minoru Maeda Cholestasis ameliorant
US5846964A (en) 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US5948884A (en) 1995-07-17 1999-09-07 C-Chem Ag Cyclosporin derivatives with anti-HIV effect
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
HUP0102833A3 (en) * 1998-06-12 2002-03-28 Chem Ag C Cyclosporins, process for preparation thereof and their use
FR2780061B1 (fr) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
WO2000001715A1 (fr) 1998-07-01 2000-01-13 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
DK0982035T3 (da) * 1998-08-18 2004-06-28 Panacea Biotec Ltd Cyclosporinpræparater
WO2001047883A1 (fr) 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a cycles accoles et leur utilisation comme medicaments
CN102372764A (zh) 2000-07-21 2012-03-14 先灵公司 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
UA79764C2 (en) 2001-11-27 2007-07-25 Anadys Pharmaceuticals Inc 3-?-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
US6987090B2 (en) 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
US20050009877A1 (en) 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
CA2573207C (en) 2004-07-14 2013-04-16 Novartis Ag Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv)
US20060025267A1 (en) 2004-07-29 2006-02-02 Mircea Gradu Differential with torque vectoring capabilities
NZ554412A (en) 2004-10-01 2011-01-28 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
DK1802650T3 (da) * 2004-10-01 2012-02-06 Scynexis Inc 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
CN101076350A (zh) 2004-12-23 2007-11-21 诺瓦提斯公司 用于hcv治疗的组合物
KR20070089954A (ko) 2004-12-23 2007-09-04 노파르티스 아게 플라비비리대 치료용 화합물
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
US7754685B2 (en) 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
DK2023918T3 (da) 2006-05-19 2011-04-26 Scynexis Inc Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes

Also Published As

Publication number Publication date
AU2006299426B2 (en) 2012-07-26
JP2009510129A (ja) 2009-03-12
WO2007041632A2 (en) 2007-04-12
RU2008117157A (ru) 2009-11-10
AU2006299426A1 (en) 2007-04-12
US7754685B2 (en) 2010-07-13
WO2007041632A3 (en) 2007-12-13
CA2623865A1 (en) 2007-04-12
JP5517454B2 (ja) 2014-06-11
US20070173440A1 (en) 2007-07-26
NZ567262A (en) 2011-12-22
RU2440822C2 (ru) 2012-01-27
CN105169369A (zh) 2015-12-23
CN105169369B (zh) 2019-10-18
EP1933859A2 (en) 2008-06-25
KR20080059270A (ko) 2008-06-26
BRPI0616476A2 (pt) 2011-06-21
ZA200803493B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
IL190478A0 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
IL257622B (en) Methods and preparations for the treatment of persistent infections
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
ZA200709727B (en) Compounds and methods for the treatment of prevention of flavivirus infections
IL197804A0 (en) Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
EP2099449A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES THAT COME WITH IMPOTENCE
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
PL1965816T3 (pl) Kompozycje farmaceutyczne i sposoby leczenia lub zapobiegania chorobom związanym ze szczawianami
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
IL195272A0 (en) Methods and compositions for the treatment of viral infections
GB0718446D0 (en) Compositions and methods for the treatment of infection
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
EP1991270A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CACHEXIA
IL187405A0 (en) Methods and compositions for the treatment of pain
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
IL183893A0 (en) Pharmaceutical compositions for the treatment of cellulite
ZA200703157B (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
ZA200707955B (en) Methods and pharmaceutical compositions for the treatment of neurological damage
HUE026600T2 (hu) Készítmények és eljárások virális hepatitis kezelésére
PL1812797T3 (pl) Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees